Parabilis Medicines, Inc. (NasdaqGS: PBLS)
Health Care · Biotechnology · US
$39.23
+2.08% today · +24.1% 1Y
Parabilis Medicines, Inc. (NasdaqGS: PBLS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.85B and employs 145 people.
Over the last twelve months the share price has gained 24.1%, trading between 24.51 and 41.49.
PBLS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.85B
- Revenue (TTM)
- $148.00K
- P/E
- —
- EPS
- -23.45
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $41.49
- 52-week low
- $24.51
- Avg volume (3M)
- —
- Shares outstanding
- 123.53M
- Employees
- 145
- Next earnings
- —
About Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
- ISIN
- US6989551014
- Founded
- 2015
- Listed since
- Jun 10, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.